Skip to main content
Erschienen in: MMW - Fortschritte der Medizin 1/2018

15.01.2018 | Myalgie | FORTBILDUNG . SCHWERPUNKT

Leitfaden

Sechs Maßnahmen bei Statin-assoziierten Muskelschmerzen

verfasst von: Prof. Dr. med. Gerald Klose

Erschienen in: MMW - Fortschritte der Medizin | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Problem Statin-assoziierter Muskelschmerzen und damit die Sorge, dass Ihrem Patienten das präventive Potenzial der Statintherapie entgeht, kennen Sie sicherlich auch. Der nachfolgende Beitrag zeigt auf, wie Sie das Problem Schritt für Schritt in den Griff bekommen.
Literatur
1.
Zurück zum Zitat Yusuf S, Why do people not take life-saving medications? The case of statins. Lancet. 2016 Sep 3;388(10048):943–5CrossRefPubMed Yusuf S, Why do people not take life-saving medications? The case of statins. Lancet. 2016 Sep 3;388(10048):943–5CrossRefPubMed
2.
Zurück zum Zitat Collins R et al., Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532–2561CrossRefPubMed Collins R et al., Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532–2561CrossRefPubMed
3.
Zurück zum Zitat Stroes ES et al., Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1;36(17):1012–22CrossRefPubMedPubMedCentral Stroes ES et al., Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1;36(17):1012–22CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Hovingh GK et al., Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis. 2016 Feb;245:111–7CrossRefPubMed Hovingh GK et al., Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis. 2016 Feb;245:111–7CrossRefPubMed
5.
Zurück zum Zitat Laufs U et al, Behandlungsoptionen bei Statin-assoziierten Muskelbeschwerden. Dtsch Ärztebl Int. 2015 Oct 30;112(44):748–55PubMedPubMedCentral Laufs U et al, Behandlungsoptionen bei Statin-assoziierten Muskelbeschwerden. Dtsch Ärztebl Int. 2015 Oct 30;112(44):748–55PubMedPubMedCentral
6.
Zurück zum Zitat Parker BA et al., Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96–103CrossRefPubMed Parker BA et al., Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96–103CrossRefPubMed
7.
Zurück zum Zitat Moriarty PM et al., Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758–769CrossRefPubMed Moriarty PM et al., Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758–769CrossRefPubMed
8.
Zurück zum Zitat Nissen SE et al., Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580–90CrossRefPubMed Nissen SE et al., Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580–90CrossRefPubMed
9.
Zurück zum Zitat Gupta A et al., Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017 Jun 24;389(10088):2473–2481CrossRefPubMed Gupta A et al., Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017 Jun 24;389(10088):2473–2481CrossRefPubMed
10.
Zurück zum Zitat 2014 arznei-telegramm, publiziert am 9. Mai 2014 2014 arznei-telegramm, publiziert am 9. Mai 2014
11.
Zurück zum Zitat Laufs U et al., Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler Suppl. 2017 Apr;26:45–55CrossRefPubMed Laufs U et al., Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler Suppl. 2017 Apr;26:45–55CrossRefPubMed
12.
Zurück zum Zitat du Souich P et al, Myotoxicity of statins: Mechanism of action. Pharmacol Ther. 2017 Jul;175:1–16CrossRefPubMed du Souich P et al, Myotoxicity of statins: Mechanism of action. Pharmacol Ther. 2017 Jul;175:1–16CrossRefPubMed
13.
Zurück zum Zitat Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670–81CrossRef Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670–81CrossRef
14.
Zurück zum Zitat Daskalopoulou SS et al, Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008 Sep;29(17):2083–91CrossRefPubMed Daskalopoulou SS et al, Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008 Sep;29(17):2083–91CrossRefPubMed
15.
Zurück zum Zitat Shalev V et al., Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009 Feb 9;169(3):260–8CrossRefPubMed Shalev V et al., Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009 Feb 9;169(3):260–8CrossRefPubMed
16.
Zurück zum Zitat Turner RM et al., Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol. 2017 Jan - Feb;11(1):204–214CrossRefPubMedPubMedCentral Turner RM et al., Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol. 2017 Jan - Feb;11(1):204–214CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Serban MC et al., Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017 Mar 21;69(11):1386–1395CrossRefPubMed Serban MC et al., Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017 Mar 21;69(11):1386–1395CrossRefPubMed
18.
Zurück zum Zitat Nissen SE, Statin Denial: An Internet-Driven Cult With Deadly Consequences. Ann Intern Med. 2017 Aug 15;167(4):281–282CrossRefPubMed Nissen SE, Statin Denial: An Internet-Driven Cult With Deadly Consequences. Ann Intern Med. 2017 Aug 15;167(4):281–282CrossRefPubMed
19.
Zurück zum Zitat Nielsen SF et al., Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016 Mar 14;37(11):908–916CrossRefPubMed Nielsen SF et al., Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016 Mar 14;37(11):908–916CrossRefPubMed
20.
Zurück zum Zitat Landmesser, U et al., 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2017 Oct 16 doi: 10.1093/eurheartj/ehx549. [Epub ahead of print Landmesser, U et al., 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2017 Oct 16 doi: 10.1093/eurheartj/ehx549. [Epub ahead of print
21.
Zurück zum Zitat Irvin JC The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacological Research 2017 Irvin JC The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacological Research 2017
22.
Zurück zum Zitat Khayznikov M et al., Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci. 2015 Mar;7(3):86–93CrossRefPubMedPubMedCentral Khayznikov M et al., Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci. 2015 Mar;7(3):86–93CrossRefPubMedPubMedCentral
Metadaten
Titel
Leitfaden
Sechs Maßnahmen bei Statin-assoziierten Muskelschmerzen
verfasst von
Prof. Dr. med. Gerald Klose
Publikationsdatum
15.01.2018
Verlag
Springer Medizin
Erschienen in
MMW - Fortschritte der Medizin / Ausgabe 1/2018
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI
https://doi.org/10.1007/s15006-018-0090-3

Weitere Artikel der Ausgabe 1/2018

MMW - Fortschritte der Medizin 1/2018 Zur Ausgabe

AUS DER PRAXIS VON HAUSARZT ZU HAUSARZT

Bald dürfen wir auch noch Notfalldatensätze managen

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.